Our International Affiliates
The Canadian Depression Research and Intervention Network CDRIN
CDRIN was founded through a partnership between the following organizations:
- Mood Disorders Society of Canada (MDSC)
- Mental Health Commission of Canada (MHCC) and
- The Royal's Institute of Mental Health Research (IMHR)
CDRIN is also actively engaging international partners, including the NNDC, and utilizing their mature organizational structures to ensure that knowledge is shared globally. These collaborations will ensure there is a deeper world understanding of depression, its causes and its treatments.
The ultimate outcome expected from a 10-year window of CDRIN and partner activity is “to discernibly improve service delivery and outcomes in relation to prevention and treatment for persons likely to experience or experiencing Depression or PTSD.”
Pan-Canadian Regional Depression Research Hubs
The establishment of eight pan-Canadian Regional Depression Research Hubs (HUBs) is aimed at creating a networked and collaborative environment through which new enabling approaches (mechanisms and tools) can be used to refine research priorities and facilitate the translation of results into practice. In practical terms, it is anticipated that the research capacities, expertise and other advantages combined in HUBs will provide CDRIN with a competitive edge in the pursuit of funding and partnerships for research, knowledge transfer and educational endeavors.
KUM is the University Hospital of the prestigious Ludwigs Maximilians University of Munich. With more than 2.000 beds, the University Hospital of Munich (KUM) is a highly advanced hospital with currently 28 clinics, twelve institutes and seven departments. In addition, 48 interdisciplinary centers work together across academic boundaries. With its two campuses in Grosshadern and in the city center, it is one of the largest hospitals in Europe. Together with the Medical Faculty of the Ludwig-Maximilians-University of Munich, the KUM is one of the leading medical centers in Germany and internationally.
At the Institute of Psychiatric Phenomics and Genomics (IPPG) we are primarily interested in possible genetical and neurobiological determinants of the course of severe psychiatric disorders. The findings of this research will contribute to the knowledge, why relapses occur under hitherto existing therapeutic strategies and why single patients do not respond to specific treatment processes.
After the German Research Society (DFG) had initiated the establishment of the Clinical Research Group 241 (KFO 241) starting in January 2012, KFO 241 featured a multidisciplinary panel of both clinical and basic science researchers, closely working together toward the common goal of unraveling key factors determining the disease course in schizophrenia and bipolar disorder. For both diseases, course and outcome are of utmost importance and clinical relevance as they determine the individual and societal burden of these disorders. Yet, a thorough incorporation of course into research strategies remains a scarcity in psychiatric research, in particular biological research. Most achievements in this field over the last decades have been based on cross-sectional approaches. The recent successes in psychiatric genetics or imaging genetics can be attributed to collaborative strategies employing harmonized approaches and large sample sizes. The research mission of the KFO 241 has been fueled by the desire to bring these hallmarks of success to the research of course and outcome in schizophrenia and bipolar disorder to foster a more complete understanding of these disorders.
Over the last years, the research groups have been addressing this scientific goal from various angles and have managed to create a unique environment ideally suited to tackle this widely neglected topic. The research environment is characterized by novel IT-infrastructural solutions for the recruitment of patients and control individuals, multisite phenotyping, sophisticated biobanking and the protection of sensitive personal data.
PsyCourse now continues this successful work as a two-site consortium with a number of researchers formerly not involved, which bring additional expertise and hail from leading institutions in their respective fields. Furthermore, PsyCourse extends the phenotypic spectrum by also including major depressive disorder due to an increasing body of evidence of shared etiological mechanisms across these three disorders.